Clinical trial of hTERT-derived peptide vaccine for hepatocellular carcinoma
Phase 1
- Conditions
- Hepatocellular carcinoma (HCC)
- Registration Number
- JPRN-UMIN000003511
- Lead Sponsor
- Department of Gastroenterology, Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe complications associated with heart, kidney, lung, blood and coagulability 2)Infection of HIV 3)Past medical history of malignancy 4)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks 5)Past medical history of Immunodeficiency, splenectomy and radiation of spleen 6)medical treatments with steroid or anti-histamine 7)Patients who are during lactation 8)Patients who are during pregnancy and expected pregnancy 9)Past history of organ transplantation 10)Patients who are predicted a difficulty of following clinical course 11)Patients who are judged inappropriate for clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of adverse events and immune responses
- Secondary Outcome Measures
Name Time Method Evaluation of recurrence rate and tumor marker